Plain-English translation of NCT07185841 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new oral medication called HX9428 to see if it can safely treat wet age-related macular degeneration (wAMD), a serious eye condition that damages your central vision. The trial has two parts: first, doctors will test different doses to find what is safe and well-tolerated; then, if the medication shows promise, they will study whether it actually helps improve vision in patients like you.
Most current treatments for wet macular degeneration require injections directly into the eye, which can be uncomfortable and inconvenient for patients. This trial is exploring whether an oral pill could offer an easier alternative that still effectively stops vision loss.
You likely qualify if…
You likely don't qualify if…
You will take oral HX9428 tablets by mouth, starting at a low dose that may gradually increase depending on how well you tolerate the medication. The trial will involve multiple clinic visits where your eyes will be examined with imaging tests to check for safety and how well the medication is working. Participation spans both a safety-testing phase and an effectiveness-testing phase, with doctors carefully monitoring your vision and overall health throughout.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Fujian Haixi Pharmaceuticals Co., Ltd.
Enrollment target
~198 participants
Started
July 2025
Primary completion
July 2028
Age range
50 Years – 85 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Junqing Li
Beijing Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.